What is Erste Group Bank’s Estimate for NVO FY2027 Earnings?

Novo Nordisk A/S (NYSE:NVO) – Stock analysts at Erste Group Bank dropped their FY2027 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research report issued to clients and investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.18 per share for the year, down from their previous forecast of $3.22. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.41 per share.

NVO has been the subject of several other research reports. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a report on Tuesday, March 3rd. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

NVO opened at $47.92 on Wednesday. The company’s 50 day simple moving average is $44.09 and its 200 day simple moving average is $45.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $71.79. The stock has a market capitalization of $213.96 billion, a PE ratio of 11.25, a P/E/G ratio of 4.37 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $25,000. Scarborough Advisors LLC purchased a new stake in Novo Nordisk A/S during the first quarter worth approximately $26,000. WealthCollab LLC increased its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $28,000. Finally, Maseco LLP purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Shantha Biologics said it signed an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, signaling continued demand and operational expansion for NVO’s diabetes/weight-loss product supply chain. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
• Positive Sentiment: Medicare will begin covering obesity drugs for eligible seniors under a temporary program, which could expand access to GLP-1 treatments and broaden the addressable market for Novo Nordisk’s Wegovy franchise. Medicare will start covering obesity drugs for the first time. Here’s what patients should know
• Positive Sentiment: Citi said Novo Nordisk’s oral Wegovy pill is gaining prescriptions quickly in the U.S., suggesting strong early traction in the competitive oral GLP-1 market. Citi says Wegovy pill outpacing rivals as oral GLP-1 race heats up
• Neutral Sentiment: Several articles discussed Novo Nordisk versus rivals like Viking and broader obesity/biotech trends, but these were mostly comparative or thematic pieces rather than direct company-specific catalysts. Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
• Neutral Sentiment: Novo Nordisk also announced an ongoing share repurchase program, which supports capital returns but is not a major new surprise. Novo Nordisk A/S – share repurchase programme
• Negative Sentiment: Coverage focusing on Eli Lilly’s broader growth prospects and new launches highlights intensifying competition in the GLP-1 market, which could pressure Novo Nordisk’s long-term market share. Can Eli Lilly’s New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.